Myriad to Present Seven Studies at the ASHG Annual Meeting

SALT LAKE CITY, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that there will be seven poster presentations featured at American Society for Human Genetics (ASHG) meeting being held Oct. 6 to 10, 2015 in Baltimore, Md.

"At Myriad, we are passionately committed to providing the most accurate hereditary cancer tests through extensively validated laboratory and variant interpretation processes. We have spent almost two decades of research to provide the most sophisticated and comprehensive variant classification program," said Rick Wenstrup, M.D., chief medical officer, Myriad Genetics. "We look forward to presenting these seven new studies at ASHG as we continue to advance the state-of-the-art in variant classification with innovative new approaches."

A list of the Myriad presentations at ASHG (#ASHG15) follows:

Poster Presentations

  • Title: RNA functional studies for the classification of germline variants of uncertain significance that may impair splicing.
    Date: Wednesday, Oct. 7, 2015: 5:00 to 6:00 p.m. ET.
    Location: Poster 2639W.
  • Title: No evidence for a difference in the severity of cancer history for carriers of missense versus truncating pathogenic variants in ATM.
    Date: Thursday, Oct. 8, 2015: 12:00 to 1:00 p.m. ET.
    Location: Poster 2750T.
  • Title: Detection of large rearrangements in a pan-cancer gene panel using next generation sequencing.
    Date: Thursday, Oct. 8, 2015: 12:00 to 1:00 p.m. ET.
    Location: Poster 2018T.
  • Title: Comparison of a literature search algorithm and curated publication database with the literature content of other locus specific databases.
    Date: Thursday, Oct. 8, 2015: 12:00 to 1:00 p.m. ET.
    Location: Poster 1739T.
  • Title: Analytical validation of a saliva collection and DNA extraction protocol increases accessibility to hereditary pan-cancer panel testing.
    Date: Thursday, Oct. 8, 2015: 12:00 to 1:00 p.m. ET.
    Location: Poster 1985T.
  • Title: Identification of retrotransposon insertion mutations in hereditary cancer.
    Date: Thursday, Oct. 8, 2015: 12:00 to 1:00 p.m. ET.
    Location: Poster 2592T.
  • Title: Does this patient need to be tested for Lynch Syndrome? Assessing the reliability of family history for ascertainment.
    Date: Friday, Oct. 9, 2015: 11:45 a.m. to 12:45 p.m. ET.
    Location: Poster 2082F.

For more information about these presentations, including a complete list of abstracts and posters, please visit the ASHG website at

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to characterizing genomic changes in cancer, improving variant classification and sharing that knowledge with the medical and scientific community; presenting seven new studies at ASHG, advancing the state-of-the-art in hereditary cancer testing or improving patient care; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers' reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2015, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

CONTACT: Media Contact: Ron Rogers (908) 285-0248 Investor Contact: Scott Gleason (801) 584-1143

Source:Myriad Genetics, Inc.